The new product development contracts are part of the Antiviral Program for Pandemics (APP), which aims to accelerate the discovery, development, and manufacturing of antiviral medicines.

The following are the awardees:

• Microbiotix for "Optimization of Broad-Spectrum Filovirus Inhibitors that Target Viral Glycoprotein"
• Oregon Health and Science University for "Development of a Novel 2-Pyrimidone (SRI-42718) as a Potent Inhibitor of Chikungunya Virus Infection and Disease"
• Baruch S. Blumberg Institute for "Development of an Orally Available Antiviral Drug for Yellow Fever"

The institutions will develop promising antiviral candidates from late-stage preclinical studies to investigational new drug application-enabling activities and clinical testing.

For more information about the APP, please visit the program's webpage.

NIH grant to fund early Alzheimer's detection
A $1.2 million National Institutes of Health (NIH) grant will help Penn State-led researchers explore the development of a machine-learning system to...

UVA gets $3.6M grant to study Crohn's disease
The National Institutes of Health has awarded University of Virginia (UVA) Children's Hospital a $3.6 million grant to better understand and treat Crohn's...

$11.3M NIH grant funds national project to investigate molecular origins of pain
A new National Institutes of Health (NIH)-funded project will investigate the origins of human pain at the cellular and molecular level -- potentially...

NIH awards $285M for innovative biomedical research projects
The National Institutes of Health’s High-Risk, High-Reward Research program, part of its Director’s Awards, has awarded approximately $285 million in...